<DOC>
	<DOCNO>NCT00320515</DOCNO>
	<brief_summary>This multicenter , single arm , open-label Phase 1/2 study pemetrexed plus cisplatin patient unresectable , advanced gastric cancer prior palliative chemotherapy . Phase 1 design determine optimal dose pemetrexed phase 2 , complete total 60 qualified patient enrol phase 2 study . The treat physician determine maximum number cycle pemetrexed plus cisplatin patient may receive study .</brief_summary>
	<brief_title>Study Pemetrexed Plus Cisplatin Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histological proven diagnosis adenocarcinoma stomach Stage IV disease amenable curative surgery . Disease status must measurable disease define Response Evaluation Criteria In Solid Tumors ( RECIST ) criterion . Performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) scale . Adequate organ function Prior palliative chemotherapy advance gastric cancer . Pregnancy breast feeding . Known suspected brain metastasis secondary primary malignancy Inability interrupt aspirin , nonsteroidal antiinflammatory agent 5day period . Inability unwillingness take folic acid vitamin B12 supplementation . Concurrent administration tumor therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>